Viridian and Kissei Pharmaceutical have signed an exclusive partnership and license agreement for advancing veligrotug and VRDN-003.

We spoke to BBG Advanced Therapies COO Adrienne Mendoza to learn how one company is tackling the challenges of cell therapies.

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

ViroCell Biologics has partnered AvenCell Therapeutics for development of new allogeneic CAR-T therapies to treat blood cancers.

GSK's Q2 results show that sales of its specialist oncology assets have risen by 42%, while general drug sales were down 6%.

Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...